Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Payables (2016 - 2025)

Historic Payables for Ocular Therapeutix (OCUL) over the last 13 years, with Q4 2025 value amounting to $4.2 million.

  • Ocular Therapeutix's Payables fell 52.68% to $4.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was $4.2 million, marking a year-over-year decrease of 52.68%. This contributed to the annual value of $4.2 million for FY2025, which is 52.68% down from last year.
  • As of Q4 2025, Ocular Therapeutix's Payables stood at $4.2 million, which was down 52.68% from $6.3 million recorded in Q3 2025.
  • Over the past 5 years, Ocular Therapeutix's Payables peaked at $12.4 million during Q1 2021, and registered a low of $3.4 million during Q1 2022.
  • In the last 5 years, Ocular Therapeutix's Payables had a median value of $4.5 million in 2021 and averaged $5.1 million.
  • As far as peak fluctuations go, Ocular Therapeutix's Payables skyrocketed by 15324.65% in 2021, and later plummeted by 7251.25% in 2022.
  • Ocular Therapeutix's Payables (Quarter) stood at $4.6 million in 2021, then grew by 11.56% to $5.1 million in 2022, then dropped by 14.33% to $4.4 million in 2023, then fell by 4.85% to $4.2 million in 2024, then dropped by 0.53% to $4.2 million in 2025.
  • Its Payables was $4.2 million in Q4 2025, compared to $6.3 million in Q3 2025 and $5.9 million in Q2 2025.